China-based Contract Research Organization (CRO) Tigermed (SHE: 300347, HKG: 3347) has announced the opening of its international headquarters in Hong Kong, signifying a significant milestone in the company’s efforts to globalize its operations and corporate development. The new international HQ is set to enhance Tigermed’s ability to coordinate and manage global projects, drive business expansion, and empower customers on a global scale.
Enhancing Global Project Management and Business Expansion
The establishment of the international headquarters in Hong Kong will streamline Tigermed’s operations, enabling more efficient coordination and management of global projects. This strategic move is expected to invigorate the company’s service platform, global talent pool, supporting functions, corporate culture, and other aspects of its international presence.
A Decade of Partnerships and Innovation in Hong Kong
Tigermed has had a presence in Hong Kong since 2011, partnering with local researchers and clinical sites for over a decade to advance innovative product development. This history of collaboration has laid a strong foundation for the company’s expansion and commitment to the region. In August 2020, Tigermed further solidified its presence in Hong Kong with a listing on the Hong Kong Stock Exchange (HKSE), marking the establishment of the company’s “A + H” dual-capital platform.
Demonstrating Commitment to Global Research Capabilities
The opening of the Tigermed HQ in Hong Kong is a testament to the firm’s dedication to expanding its research capabilities globally. This move is designed to build a comprehensive service platform that caters to the needs of a diverse and expanding client base. By leveraging its international headquarters, Tigermed aims to strengthen its position as a leading global CRO, providing full-spectrum services to clients worldwide.-Fineline Info & Tech
